Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa long-term extension in solid tumors
CTR20220946Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bintrafusp alfa in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), cholangiocarcinoma (CCA), Cervical Cancer (CC), sponsored by Merck KGaA. Started Apr 2022; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)cholangiocarcinoma (CCA)Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20220946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220946.